MDI-2517

MDI Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	MDI-2517
Sponsor	MDI Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants (PHASE1)
SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MDI-2517 CI brief — competitive landscape report
MDI-2517 updates RSS · CI watch RSS
MDI Therapeutics, Inc. portfolio CI